(BBH) Biotech - Overview
Etf: Biotech, ETF, Stocks, Nasdaq
Dividends
| Dividend Yield | 0.50% |
| Yield on Cost 5y | 0.50% |
| Yield CAGR 5y | 24.57% |
| Payout Consistency | 66.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.3% |
| Relative Tail Risk | 1.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.74 |
| Alpha | 6.44 |
| Character TTM | |
|---|---|
| Beta | 0.659 |
| Beta Downside | 0.556 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.74% |
| CAGR/Max DD | 0.34 |
Description: BBH Biotech December 29, 2025
The VanEck Biotech ETF (NASDAQ: BBH) is a non-diversified fund that commits at least 80 % of its net assets to securities tracking its Biotech Index, which consists of U.S. exchange-listed biotech companies-including medium-cap and foreign issuers listed in the U.S.
Key metrics (as of the latest quarterly report) show an expense ratio of 0.35 % and assets under management of roughly $1.2 billion, with top holdings such as Moderna, CRISPR Therapeutics, and Illumina. The biotech sector’s growth is driven by an estimated 10 % CAGR in global gene-therapy spending and a historically high FDA approval rate for novel therapies, which together underpin demand for the underlying equities.
For a deeper, data-rich perspective on BBH’s role in a biotech allocation, you might explore ValueRay’s analytical platform.
What is the price of BBH shares?
Over the past week, the price has changed by +1.13%, over one month by +2.88%, over three months by +9.84% and over the past year by +23.97%.
Is BBH a buy, sell or hold?
What are the forecasts/targets for the BBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 207.4 | 4% |
BBH Fundamental Data Overview February 05, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 393.1m USD (393.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 393.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 393.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.34% (E(393.1m)/V(393.1m) * Re(8.34%) + (debt-free company))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)